US FDA accepts Astellas' NDA for tacrolimus ER capsules pharmabiz.com The US Food and Drug Administration (FDA) has accepted Astellas Pharma US, Inc.'s, New Drug Application (NDA) for tacrolimus extended release capsules, for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver ... |
